Brief: Biomx Announces Positive Topline Results From Part 2 Of The Phase 1B/2A Trial Evaluating Bx004

Biomx

29/11/2023 12:58

Nov 29 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PART 2 OF THE PHASE 1B/2A
TRIAL
EVALUATING BX004 FOR TREATMENT OF CHRONIC PULMONARY INFECTIONS IN PATIENTS WITH
CYSTIC FIBROSIS
    * BIOMX INC - BX004 THERAPY WAS SAFE AND WELL-TOLERATED
    * BIOMX INC - PLANS TO ADVANCE BX004 PROGRAM INTO PIVOTAL PHASE 2B/3 TRIAL
    * BIOMX INC - PLANS TO ADVANCE BX004 PROGRAM INTO PIVOTAL PHASE 2B/3 TRIAL
    * BIOMX -TREATMENT WITH BX004 ACHIEVED P. AERUGINOSA CULTURE CONVERSION TO
NEGATIVE AT END OF 10 DAYS OF TREATMENT IN 3 PATIENTS VERSUS NONE FOR PLACEBO
    * BIOMX INC - IN PART 2 OF STUDY, BX004 SHOWED CLINICALLY MEANINGFUL
IMPROVEMENT
IN PULMONARY FUNCTION COMPARED TO PLACEBO
    * BIOMX INC - BX004 VERSUS. PLACEBO SHOWED A POSITIVE CLINICAL EFFECT IN A
PREDEFINED SUBGROUP OF PATIENTS WITH REDUCED BASELINE LUNG FUNCTION
    * BIOMX INC - NO EVIDENCE OF TREATMENT-RELATED PHAGE RESISTANCE WAS OBSERVED
IN
PATIENTS TREATED WITH BX004 COMPARED TO PLACEBO

Source text for Eikon:  ID:nGNX9293js 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com;))